Izotropic (IZO) AI Stock Analysis

• Market Cap: C$15.25M
• Dividend Yield: N/A
• Average Volume (3M): 43.33K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.01
• Revenue Growth: N/A
• EPS Growth: 11.68%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.01
• Shares Outstanding: 67,784,676
• 10 Day Avg. Volume: 24,438
• 30 Day Avg. Volume: 43,328
• PEG Ratio: -0.05
• Price to Book (P/B): -2.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -22.10
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: C$0.21 ▼(-23.93% Downside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is mainly pressured by very weak financial performance (no revenue, persistent losses, negative free cash flow, and negative equity). Technical indicators also point to a bearish trend with weak momentum. Valuation provides limited offset since the company is loss-making (negative P/E) and has no dividend yield data.

Positive Factors

Dedicated Product Focus

A focused product strategy—developing a dedicated breast CT platform—gives Izotropic a clear, defensible niche in breast imaging. Specialization can enable deeper clinical validation, stronger OEM/clinician relationships, and differentiation versus general imaging vendors, aiding sustainable adoption.

Improving Cash Burn Trend

An improving free cash flow growth rate indicates management is reducing burn and moving toward tighter operational control. If sustained, this trend lessens refinancing frequency, extends runway for clinical development, and lowers dilution risk—key for a capital-intensive medtech developer.

Progress Toward Lower Losses

Year-over-year improvement in net losses shows some operational progress and better cost or development execution. Continued reduction of structural losses is necessary to reach breakeven; this trajectory, if maintained, supports eventual transition from development spend to commercialization investments.

Negative Factors

No Revenue

Lack of revenue means the business remains pre-commercial and dependent on R&D and financing cycles. Without product sales, the company cannot self-fund operations; prolonged pre-revenue status raises execution risk around regulatory clearance, clinical adoption, and the ability to prove repeatable commercial economics.

Weak Balance Sheet

Negative equity and a small asset base create elevated solvency risk and limit flexibility. With debt present and scant assets, the company is vulnerable to funding shocks and may face higher-cost financing or dilution, constraining its ability to sustain lengthy clinical programs or scale commercialization.

Negative Cash Generation

Persistent negative operating and free cash flow forces reliance on capital markets or partners. This structural cash shortfall can delay clinical trials, slow commercialization, and increase dilution risk; until operations generate positive cash, financing needs remain a central strategic constraint.

Izotropic Business Overview & Revenue Model

Company Description

Izotropic Corporation, a MedTech company, commercializes diagnostic products for breast cancer. It develops and commercializes breast CT Imaging system; and 3D CT breast imaging platform for the earlier detection and diagnosis of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.

How the Company Makes Money

null

Izotropic Financial Statement Overview

Summary

Financials are weak: TTM shows no revenue, ongoing operating and net losses, and negative gross profit. The balance sheet is strained with negative equity and meaningful debt relative to a small asset base, increasing solvency/financing risk. Cash flow remains negative (operating and free cash flow), indicating continued reliance on external funding despite some improvement in burn rate versus prior periods.

Income Statement

TTM (Trailing-Twelve-Months) results show no revenue and continued operating losses (EBIT of about -2.5M and net loss of about -2.7M), indicating the business is still in a heavy investment/burn phase. While annual net losses improved versus 2022–2023 levels, losses widened again versus 2024 and gross profit remains negative, suggesting limited progress toward self-sustaining operations.

Balance Sheet

The balance sheet is strained: stockholders’ equity is negative in the most recent periods (TTM equity about -5.5M) alongside meaningful debt (TTM total debt about 3.0M). Total assets are relatively small (about 0.45M TTM), and the negative equity position implies elevated financing and solvency risk, even though debt levels have not exploded year-over-year.

Cash Flow

Cash generation remains weak with negative operating cash flow and negative free cash flow in TTM (roughly -1.0M), meaning the company is still reliant on external funding. A positive TTM free cash flow growth rate suggests the cash burn rate improved versus the prior period, but cash flow is still firmly negative and not yet showing a path to consistent funding from operations.

Breakdown	TTM	Jul 2025	Jul 2024	Jul 2023	Jul 2022	Jul 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-38.31K	-48.90K	-59.07K	-30.88K	-6.87K	-1.63K
EBITDA	-2.43M	-2.14M	-1.60M	-5.33M	-6.63M	-4.97M
Net Income	-2.75M	-3.14M	-1.56M	-5.66M	-6.67M	-4.98M
Balance Sheet
Total Assets	447.06K	414.73K	232.38K	442.11K	2.27M	4.69M
Cash, Cash Equivalents and Short-Term Investments	229.86K	274.11K	38.60K	165.69K	1.86M	4.06M
Total Debt	2.97M	2.76M	2.06M	2.14M	2.03M	0.00
Total Liabilities	5.95M	5.27M	4.08M	3.52M	2.64M	169.28K
Stockholders Equity	-5.50M	-4.86M	-3.85M	-3.07M	-374.59K	4.52M
Cash Flow
Free Cash Flow	-1.01M	-637.37K	-593.57K	-3.30M	-4.79M	-3.08M
Operating Cash Flow	-1.01M	-636.23K	-593.57K	-3.27M	-4.76M	-3.08M
Investing Cash Flow	-1.14K	-1.14K	0.00	-36.18K	-24.23K	0.00
Financing Cash Flow	1.13M	872.78K	468.18K	1.61M	2.58M	6.53M

Izotropic Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:IZO, the sentiment is Negative. The current price of 0.28 is above the 20-day moving average (MA) of 0.23, above the 50-day MA of 0.24, and below the 200-day MA of 0.30, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.09 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:IZO.

Izotropic Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VPT	50 Neutral	C$21.58M	-5.28	106.68%	―	28.59%	23.46%
BUX	48 Neutral	C$64.11M	-32.47	―	―	-21.89%	26.36%
EDT	45 Neutral	C$374.48M	-3.46	―	―	34.85%	-62.50%
IZO	44 Neutral	C$15.25M	-9.29	53.94%	―	―	11.68%
PINK	42 Neutral	C$52.97M	-1.50	-181.70%	―	209.29%	35.38%
SONA	41 Neutral	C$50.33M	-21.43	-434.25%	―	―	10.97%

Izotropic Corporate Events

Izotropic Africa Pursues Moroccan Partnership to Advance Breast CT Expansion

Izotropic’s newly formed Casablanca-based venture, Izotropic Africa, is being structured to license, market, and distribute the IzoView Breast CT Imaging System and follow-on products across Africa and the Gulf Cooperation Council, with Izotropic holding a 40% stake alongside a local business group. The initiative aligns the company with regional healthcare priorities and leverages Morocco’s strategic location and industrial infrastructure to support regional expansion.

Izotropic Africa has entered partnership discussions with the Mohammed VI Foundation for Science & Health to collaborate on clinical research, regulatory advancement, and potential manufacturing and assembly of IzoView systems in Morocco. The talks include placing a US$500,000 IzoView unit at a leading Moroccan hospital for clinical evaluation, positioning Izotropic to benefit from Morocco’s new national framework to build domestic medical device manufacturing capacity, strengthen supply chains, and promote export-oriented production.

The most recent analyst rating on (TSE:IZO) stock is a Hold with a C$0.20 price target. To see the full list of analyst forecasts on Izotropic stock, see the TSE:IZO Stock Forecast page.

Izotropic Moves to Establish African and GCC Hub for Breast CT Imaging

Izotropic Corporation has signed a letter agreement with a business group to create Izotropic Africa, a Casablanca-based entity that will license, market, and distribute the IzoView Breast CT system and follow-on products across Africa and the Gulf Cooperation Council states. The move targets a rapidly growing regional market for advanced oncology imaging, where breast cancer incidence is high and mortality rates are elevated due to late diagnosis and limited access to sophisticated diagnostic tools.

Under the agreement, the business group will hold 60% of the new entity and Izotropic 40%, with both parties aiming to finalize a formal contract by April 30, 2026. The partners plan to secure a major Moroccan hospital by the first quarter of 2026 as a site for installing the first IzoView system for research, data collection, and regulatory approvals, while also evaluating local manufacturing or assembly, a strategy that could significantly extend Izotropic’s operational footprint and long-term revenue opportunities in Africa and the GCC.

The business group will lead annual business planning and engage with regional health ministries to initiate approval processes, anchoring market entry and regulatory pathways for IzoView and future products. Izotropic will provide technical, clinical, and operational support and has agreed to advance $30,000 toward an estimated first-year startup budget, with any further funding and commitments contingent on executing a formal agreement and securing financing.

The most recent analyst rating on (TSE:IZO) stock is a Hold with a C$0.19 price target. To see the full list of analyst forecasts on Izotropic stock, see the TSE:IZO Stock Forecast page.

Izotropic Raises Working Capital and Settles Debt with Equity Units

Izotropic closed a $300,000 non-brokered private placement by issuing 1.2 million units priced at $0.25, each carrying a share and three-year warrant, with proceeds earmarked for general working capital and contingent on regulatory approvals; it also plans to settle $60,000 of accrued interest on a 2022 promissory note by issuing 240,000 settlement units with identical pricing and warrant terms, pending Canadian Securities Exchange approval.

The most recent analyst rating on (TSE:IZO) stock is a Sell with a C$0.23 price target. To see the full list of analyst forecasts on Izotropic stock, see the TSE:IZO Stock Forecast page.

Izotropic Plans $300,000 Private Placement to Advance IzoView Breast CT Commercialization

Izotropic Corporation has provided a corporate update outlining its strategic priority to secure capital, with an emphasis on non-dilutive financing, to fund the commercialization of its IzoView Breast CT system and accelerate additional regulatory pathways for earlier revenue generation. As it advances due diligence with potential strategic partners for global business units, territorial and manufacturing rights, distribution agreements, and expanded regulatory approvals, the company continues to run small financings to support operations. In this context, Izotropic plans to complete a non-brokered private placement of up to 1.2 million units at $0.25 per unit for gross proceeds of up to $300,000, each unit comprising one common share and one three-year warrant exercisable at $0.25, with proceeds earmarked for general working capital and subject to standard regulatory approvals and hold periods.

The most recent analyst rating on (TSE:IZO) stock is a Sell with a C$0.23 price target. To see the full list of analyst forecasts on Izotropic stock, see the TSE:IZO Stock Forecast page.

Izotropic Shareholders Approve All AGM Resolutions and Lower Quorum Threshold

Izotropic Corporation reported that all resolutions presented at its Annual General and Special Meeting on December 29, 2025, were approved by shareholders, including the election of five directors for the coming year and the reappointment of its external auditor. Shareholders also passed an amendment to the company’s by-laws to reduce the quorum requirement for shareholder meetings from 20% to at least 1% of issued voting shares, a move aimed at mitigating persistent logistical challenges in distributing and returning voting materials, and which is expected to make it easier for the company to conduct formal business efficiently despite ongoing disruptions affecting investor communications.

The most recent analyst rating on (TSE:IZO) stock is a Hold with a C$0.26 price target. To see the full list of analyst forecasts on Izotropic stock, see the TSE:IZO Stock Forecast page.